Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002714 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002714: Completed Phase 2 study, sponsored by Stanford University.
NCT00002714 is a Phase 2 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002714, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.
Interventions
- DRUG etoposide
- DRUG doxorubicin hydrochloride
- BIOLOGICAL bleomycin sulfate
- DRUG Stanford V regimen
- DRUG mechlorethamine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-04 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002714
The ClinicalTrials.gov registry entry for NCT00002714 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00002714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002714 about?
NCT00002714 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II tria...
What is the current status of trial NCT00002714?
This trial is currently completed. It is a Phase 2 study. The study started on 1995-04. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00002714?
The interventions under investigation include: etoposide (DRUG), doxorubicin hydrochloride (DRUG), bleomycin sulfate (BIOLOGICAL), Stanford V regimen (DRUG), mechlorethamine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002714?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.